Augmented debridement for implant related chronic osteomyelitis with an absorbable, gentamycin loaded calcium sulfate/hydroxyapatite biocomposite

We report outcomes from 52 patients with chronic osteomyelitis from implant infection treated with a single stage protocol including debridement augmented with application of CERAMENT™/G biocomposite after resection of Cierny-Mader (C-M) stage III and IV chronic osteomyelitis. Mean age was 53 years with a mean follow up of 17 months. Infection was eradicated in 48 (92.3%) patients. There were four (7.7%) recurrences. Eighteen patients (35%) had a flap. Staphylococci (51%) and Enterococci (15%) were the commonest microorganisms. Local antibiotic augmentation (CERAMENT™/G biocomposite) with dead space management is effective in the treatment of implant related chronic osteomyelitis